Argenx Se (ARGX) Gains from Investment Securities (2020 - 2021)

Argenx Se's (ARGX) quarterly Gains from Investment Securities came in at -$22.3 million in Q2 2021, down 2288.01% YoY from $1.0 million in Q2 2020, and down 300.0% on a QoQ basis from $11.2 million in Q1 2021.

Argenx Se (ARGX) Gains from Investment Securities (2020 - 2021) Analysis & Trends

Argenx Se (ARGX) has 2 years of Gains from Investment Securities data on file, last reported at -$22.3 million in Q2 2021.

  • Quarterly Gains from Investment Securities fell 2288.01% year-over-year to -$22.3 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was -$13.2 million (changed N/A YoY) and the FY2025 annual result came in at -$11.6 million, down 202.06% from the prior year.
  • Gains from Investment Securities retreated to -$22.3 million in Q2 2021, from $11.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.2 million in Q1 2021 to a low of -$22.3 million in Q2 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn

Historic Data

Download Data
DateValue
Jun 30, 2021 -22.30 Mn
Jun 30, 2021 -22.30 Mn
Mar 31, 2021 11.15 Mn
Mar 31, 2021 11.15 Mn
Dec 31, 2020 -4.32 Mn
Dec 31, 2020 -4.32 Mn
Sep 30, 2020 2.25 Mn
Sep 30, 2020 2.25 Mn
Jun 30, 2020 -934,000.00
Jun 30, 2020 -934,000.00